Bristol-Myers Squibb

Global biopharmaceutical company (NYSE: BMY) focused on oncology, hematology, immunology, cardiovascular, neuroscience and fibrotic disease; marketed assets include Opdivo (nivolumab), Yervoy, Revlimid, Eliquis (apixaban with Pfizer), Pomalyst, Sprycel, Reblozyl, Sotyktu, deucravacitinib and the cardio-failure drug Camzyos; major acquisitions: Celgene ($74B, 2019), MyoKardia ($13B, 2020), Turning Point Therapeutics ($4.1B, 2022), Karuna Therapeutics ($14B, 2024), RayzeBio ($4.1B, 2024).